T&K: Wholly-owned subsidiary Huabo Kaisheng intends to win the bid for the national centralized procurement of drugsZhitong·Oct 29, 2025 at 10:20 AM301263+0.82%
T&K: Net profit loss of 5.6796 million yuan in the third quarter, a decrease of 118.57%Zhitong·Oct 28, 2025 at 10:30 AM301263+0.82%
T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trialsZhitong·Sep 25, 2025 at 09:17 AM301263+0.82%
T&K: The drug registration application for Methanesulfonic Acid Safinamide Tablets has been acceptedZhitong·Sep 18, 2025 at 08:14 AM301263+0.82%
T&K: The application for the domestic production drug registration and marketing license of Dydrogesterone Tablets has been acceptedZhitong·Sep 4, 2025 at 08:35 AM301263+0.82%
T&K released its performance for the first half of the year, with a net profit attributable to the parent company of 37.0848 million yuan, a year-on-year decrease of 56.75%Zhitong·Aug 20, 2025 at 01:18 PM301263+0.82%
T&K plans to launch an employee stock ownership plan in 2025, with a shareholding scale not exceeding 4.9751 million sharesZhitong·Aug 4, 2025 at 11:33 AM301263+0.82%
T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goalsZhitong·Aug 4, 2025 at 07:56 AM301263+0.82%
T&K: Wholly-owned subsidiary receives drug registration certificate for Alendronate Sodium TabletsZhitong·Jul 21, 2025 at 09:09 AM301263+0.82%
T&K: Registration of Pilocarpine Hydrochloride Eye Drops AcceptedZhitong·Jul 8, 2025 at 10:28 AM301263+0.82%
The innovative drug sector opened high again, Thalys has achieved a 4-day consecutive limit upZhitong·Jul 4, 2025 at 01:28 AM301263+0.82%300436-0.54%
T&K: Application for registration and listing permit of glucosamine sulfate capsules acceptedZhitong·Jun 20, 2025 at 09:19 AM301263+0.82%
T&K: Wholly-owned subsidiary increases capital and introduces external investorsZhitong·May 30, 2025 at 07:41 AM301263+0.82%
T&K's subsidiary received the acceptance notice for the drug registration of Lidocaine and Bupivacaine CreamZhitong·Apr 30, 2025 at 09:43 AM301263+0.82%
T&K released its first-quarter performance, with a net profit attributable to the parent company of 31.546 million yuan, a decrease of 30.62%Zhitong·Apr 25, 2025 at 04:08 PM301263+0.82%
